Reuters logo
BRIEF-Galectin Therapeutics receives notice of Japanese decision to grant a composition of matter patent for GR-MD-02
April 25, 2017 / 12:11 PM / 8 months ago

BRIEF-Galectin Therapeutics receives notice of Japanese decision to grant a composition of matter patent for GR-MD-02

April 25 (Reuters) - Galectin Therapeutics Inc

* Galectin Therapeutics receives notice of Japanese decision to grant a composition of matter patent for GR-MD-02

* When issued, patent will extend coverage of company’s lead compound, GR-MD-02, to Japan

* Patent coverage period extends through 2032 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below